| Year |
Citation |
Score |
| 2024 |
Lachance G, Robitaille K, Laaraj J, Gevariya N, Varin TV, Feldiorean A, Gaignier F, Julien IB, Xu HW, Hallal T, Pelletier JF, Bouslama S, Boufaied N, Derome N, Bergeron A, ... ... Fradet V, et al. The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. Nature Communications. 15: 3431. PMID 38654015 DOI: 10.1038/s41467-024-45332-w |
0.421 |
|
| 2024 |
Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Lodde M, Racine É, ... ... Fradet V, et al. A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. Communications Medicine. 4: 56. PMID 38519581 DOI: 10.1038/s43856-024-00456-4 |
0.453 |
|
| 2023 |
Savard J, Moussa H, Pelletier JF, Julien P, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Pouliot F, Lodde M, Fradet Y, Robitaille K, Fradet V. Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial. Cancer Medicine. 12: 20163-20176. PMID 37787025 DOI: 10.1002/cam4.6598 |
0.338 |
|
| 2023 |
Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, Siemens DR, Shayegan B, Klotz L, Luke PP, Niazi T, Lavallee LT, Mousavi N, Hamilton RJ, Chin JL, et al. The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis. Jacc. Cardiooncology. 5: 70-81. PMID 36875906 DOI: 10.1016/j.jaccao.2022.09.008 |
0.479 |
|
| 2022 |
Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and Translational Medicine. 12: e581. PMID 35075795 DOI: 10.1002/ctm2.581 |
0.343 |
|
| 2022 |
Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens R, Niazi T, Fradet V, Foster W, Duceppe E, Taussky D, Hamilton R, Lavallee L, Brown I, Chin J, Gopaul D, et al. Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy. The Journal of Urology. 101097JU000000000000. PMID 34978211 DOI: 10.1097/JU.0000000000002384 |
0.465 |
|
| 2021 |
Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition. 5: nzab106. PMID 34870071 DOI: 10.1093/cdn/nzab106 |
0.509 |
|
| 2021 |
Lamarre M, Tremblay T, Bansept MA, Robitaille K, Fradet V, Giguère D, Boudreau D. A glycan-based plasmonic sensor for prostate cancer diagnosis. The Analyst. PMID 34623365 DOI: 10.1039/d1an00789k |
0.44 |
|
| 2020 |
Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research : McR. PMID 33262291 DOI: 10.1158/1541-7786.MCR-20-0316 |
0.391 |
|
| 2020 |
Fervaha G, Izard JP, Tripp DA, Aghel N, Shayegan B, Klotz L, Niazi T, Fradet V, Taussky D, Lavallée LT, Hamilton RJ, Brown I, Chin J, Gopaul D, Violette PD, et al. Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 33212008 DOI: 10.5489/cuaj.6912 |
0.465 |
|
| 2020 |
Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A. Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 32569568 DOI: 10.5489/Cuaj.6388 |
0.54 |
|
| 2020 |
Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of Urology. 101097JU000000000000. PMID 31899651 DOI: 10.1097/Ju.0000000000000714 |
0.571 |
|
| 2020 |
Pinthus JH, Shayegan B, Klotz L, Siemens DR, Luke PP, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton RJ, Brown I, Chin J, Gopaul D, et al. The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. Journal of Clinical Oncology. 38: 364-364. DOI: 10.1200/Jco.2020.38.6_Suppl.364 |
0.523 |
|
| 2020 |
Pavlovich* CP, Hyndman ME, Eure G, Ghai S, Fradet V. MP75-09 MICRO-ULTRASOUND IMAGING OF MEN WITH FAMILY HISTORY OF PROSTATE CANCER The Journal of Urology. 203: e1144-e1145. DOI: 10.1097/Ju.0000000000000961.09 |
0.511 |
|
| 2020 |
Pinthus* J, Shayegan B, Siemens R, Klotz L, Luke P, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton R, Brown I, Chin J, Gopaul D, et al. PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION The Journal of Urology. 203: e270. DOI: 10.1097/Ju.0000000000000847.010 |
0.503 |
|
| 2019 |
McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P. Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical Genitourinary Cancer. PMID 31594737 DOI: 10.1016/J.Clgc.2019.07.016 |
0.309 |
|
| 2019 |
Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European Urology Oncology. PMID 31411963 DOI: 10.1016/J.Euo.2019.01.009 |
0.498 |
|
| 2019 |
Moussa H, Nguile-Makao M, Robitaille K, Guertin MH, Allaire J, Pelletier JF, Moreel X, Gevariya N, Diorio C, Desmeules P, Têtu B, Lamarche B, Julien P, Fradet V. Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. Nutrients. 11. PMID 31315273 DOI: 10.3390/Nu11071616 |
0.532 |
|
| 2019 |
Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M. Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic Oncology. PMID 30871997 DOI: 10.1016/J.Urolonc.2019.01.017 |
0.313 |
|
| 2019 |
Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Delouya G, Taussky D, Lavallee L, Johnson C, et al. PD30-03 PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH A NEW DIAGNOSIS OF PROSTATE CANCER: RATES AND PREDICTORS OF DEPRESSIVE SYMPTOMS IN THE RADICAL PC STUDY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556135.36362.37 |
0.436 |
|
| 2019 |
Pavlovich* C, Hyndman ME, Eure G, Ghai S, Fradet V. PD23-04 A MULTI-INSTITUTIONAL RANDOMIZED CONTROLLED TRIAL COMPARING NOVEL FIRST GENERATION HIGH-RESOLUTION MICRO-ULTRASOUND WITH CONVENTIONAL FREQUENCY ULTRASOUND FOR TRANSRECTAL PROSTATE BIOPSY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555772.65881.Fd |
0.341 |
|
| 2019 |
Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Duceppe E, Lavallee L, Johnson C, Chin J, et al. MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555600.69863.72 |
0.545 |
|
| 2019 |
Pavlovich C, Hyndman M, Eure G, Ghai S, Fradet V. A multi-institutional randomized controlled trial comparing novel first generation high-resolution micro-ultrasound with conventional frequency ultrasound for transrectal prostate biopsy European Urology Supplements. 18: e737. DOI: 10.1016/s1569-9056(19)30540-8 |
0.326 |
|
| 2018 |
Gevariya N, Besançon M, Robitaille K, Picard V, Diabaté L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V. Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. The Prostate. PMID 30073695 DOI: 10.1002/Pros.23706 |
0.507 |
|
| 2018 |
Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F. Increased Prostate Cancer Glucose Metabolism Detected byF-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus. PMID 29609897 DOI: 10.1016/J.Euf.2018.03.008 |
0.494 |
|
| 2018 |
Guertin MH, Robitaille K, Pelletier JF, Duchesne T, Julien P, Savard J, Bairati I, Fradet V. Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. Bmc Cancer. 18: 64. PMID 29321047 DOI: 10.1186/S12885-017-3979-9 |
0.549 |
|
| 2018 |
Gotto G, Fradet V, Drachenberg D, Sabbagh R, Rendon RA, Shayegan B, Danielson BL, Casey R, Chan K, Camacho F, Zardan A, Hew H, Feifer A. Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P). Journal of Clinical Oncology. 36: 196-196. DOI: 10.1200/Jco.2018.36.6_Suppl.196 |
0.427 |
|
| 2018 |
Lavallee E, Bergeron M, Buteau F, Duchesnay N, Blouin A, Fradet Y, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Beauregard J, Pouliot F. Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration European Urology Supplements. 17: e1510. DOI: 10.1016/S1569-9056(18)31890-6 |
0.531 |
|
| 2018 |
Lachance G, Geveriya N, Robitaille K, Bergeron A, Picard V, Leclerc M, Joly C, Fradet Y, Droit A, Marette A, Fradet V. MP70-17 DECIPHERING THE EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2261 |
0.526 |
|
| 2018 |
Beaudoin L, Gevariya N, Robitaille K, Guertin M, Pelletier J, Julien P, Fradet V. PD42-09 EFFECTS OF OMEGA-3-RICH FISH OIL (MAG-EPA) ON PROSTATE CANCER: PRELIMINARY RESULTS OF A CLINICAL TRIAL Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1962 |
0.438 |
|
| 2018 |
Hyndman ME, Pavlovich CP, Eure G, Fradet V, Ghai S. PD37-06 PROSPECTIVE VALIDATION OF PRI-MUS™, THE PROSTATE RISK IDENTIFICATION USING MICRO-ULTRASOUND PROTOCOL FOR REAL-TIME DETECTION OF PROSTATE CANCER USING HIGH-RESOLUTION MICRO-ULTRASOUND IMAGING Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1741 |
0.519 |
|
| 2017 |
Vigneault É, Savard J, Savard MH, Ivers H, Després P, Foster W, Martin AG, Fradet V. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29106365 DOI: 10.5489/Cuaj.4428 |
0.562 |
|
| 2017 |
Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y. Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5α-reductase inhibitors. Bju International. PMID 28972698 DOI: 10.1111/Bju.14041 |
0.545 |
|
| 2017 |
Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus. PMID 28753860 DOI: 10.1016/J.Euf.2017.02.007 |
0.428 |
|
| 2017 |
Vigneault É, Savard J, Savard M, Ivers H, Després P, Foster W, Martin A, Fradet V. Supplementary data: Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French- Canadian population Canadian Urological Association Journal. 11: E461-4. DOI: 10.5489/Cuaj.5101 |
0.51 |
|
| 2017 |
Morin F, Beauregard J, Bergeron M, Nguilé-Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. Journal of Clinical Oncology. 35: e590-e590. DOI: 10.1200/Jco.2017.35.6_Suppl.E590 |
0.392 |
|
| 2017 |
Feifer A, Fradet V, Drachenberg D, Gotto G, Rendon RA, Sabbagh R, Shayegan B, Danielson BL, Casey R, Zardan A, Camacho F, Hew H. Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). Journal of Clinical Oncology. 35: 238-238. DOI: 10.1200/Jco.2017.35.6_Suppl.238 |
0.337 |
|
| 2017 |
Pinthus J, Klotz L, Lukka H, Devereaux PJ, Pohl K, Roifman I, Fradet V, Siemens R, Wallington T, Bobby S, Matsumoto E, Corbett T, Duivenvoorden W, Dehghan M, Mourtzakis M, et al. MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.468 |
0.562 |
|
| 2016 |
Vigneault E, Savard J, Ivers H, Savard MH, Fradet V, Després P, Foster W, Martin AG. Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC). International Journal of Radiation Oncology, Biology, Physics. 96: E531-E532. PMID 27674940 DOI: 10.1016/J.Ijrobp.2016.06.1960 |
0.553 |
|
| 2016 |
Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, Pavlovich CP. Assessing Cancer Risk in Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Protocol of Prostate Risk Identification Using Micro-Ultrasound. The Journal of Urology. PMID 26791931 DOI: 10.1016/J.Juro.2015.12.093 |
0.533 |
|
| 2016 |
Pinthus JH, Klotz L, Lukka H, Duivenvoorden WC, Pettit S, Pohl K, Siemens DR, Fradet V, Mourtzakis M, Kavsac P, Devereaux P, Leong D. The RADICAL-PC trial. Journal of Clinical Oncology. 34: 178-178. DOI: 10.1200/Jco.2016.34.2_Suppl.178 |
0.477 |
|
| 2016 |
Wodlinger B, Ghai S, Eure G, Fradet V, Hyndman E, Mcgrath T, Pavlovich C. Micro-ultrasound of the prostate, PRI-MUS™ protocol guidance along with clinical variables: Combined approach for reducing unnecessary biopsies European Urology Supplements. 15: e1513-e1514. DOI: 10.1016/S1569-9056(16)30358-X |
0.457 |
|
| 2016 |
Wodlinger B, Ghai S, Eure G, Fradet V, Hyndman E, Mcgrath T, Pavlovich C. Using patient screening data and machine learning algorithms to improve PRI-MUS™ accuracy with micro-ultrasound-based prostate biopsies European Urology Supplements. 15: e1499-e1500. DOI: 10.1016/S1569-9056(16)30350-5 |
0.391 |
|
| 2016 |
Vigneault E, Savard J, Ivers H, Savard M, Fradet V, Després P, Foster W, Martin A. 141: Validation of a French Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC) Radiotherapy and Oncology. 120: S52-S53. DOI: 10.1016/S0167-8140(16)33540-X |
0.553 |
|
| 2015 |
Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 9: 307-14. PMID 26664661 DOI: 10.5489/Cuaj.2707 |
0.584 |
|
| 2015 |
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, Fradet V, Turgeon AF. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. Jama Oncology. 1: 1261-9. PMID 26378418 DOI: 10.1016/J.Ijrobp.2013.06.404 |
0.542 |
|
| 2015 |
Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagnostic Pathology. 10: 67. PMID 26070608 DOI: 10.1186/S13000-015-0294-0 |
0.492 |
|
| 2015 |
Allaire J, Moreel X, Labonté MÈ, Léger C, Caron A, Julien P, Lamarche B, Fradet V. Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. European Journal of Clinical Nutrition. PMID 25758837 DOI: 10.1038/Ejcn.2015.7 |
0.443 |
|
| 2015 |
Perrault L, Fradet V, Lauzon V, Lelorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis Journal of the Canadian Urological Association. 9: 307-314. DOI: 10.5489/cuaj.2707 |
0.623 |
|
| 2015 |
Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. 322 Development and validation of a post-DRE urine-based multigene signature for detection of aggressive prostate cancer prior to biopsy European Urology Supplements. 14: e322. DOI: 10.1016/S1569-9056(15)60319-0 |
0.551 |
|
| 2015 |
Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. MP1-03 VALIDATED URINE-BASED MULTIGENE SIGNATURE FOR DETECTION OF AGGRESSIVE PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.166 |
0.557 |
|
| 2014 |
Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V. IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Research and Reports in Urology. 6: 27-34. PMID 24892030 DOI: 10.2147/Rru.S58643 |
0.477 |
|
| 2014 |
Moreel X, Allaire J, Léger C, Caron A, Labonté MÈ, Lamarche B, Julien P, Desmeules P, Têtu B, Fradet V. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prevention Research (Philadelphia, Pa.). 7: 766-76. PMID 24824038 DOI: 10.1158/1940-6207.Capr-13-0349 |
0.499 |
|
| 2014 |
Ben-Zvi T, Desmeules P, Hovington H, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2514 |
0.51 |
|
| 2013 |
Mauermann J, Fradet V, Fradet Y. Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that is the question. European Urology. 64: 28-9. PMID 23159455 DOI: 10.1016/J.Eururo.2012.10.047 |
0.4 |
|
| 2013 |
Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. European Urology. 64: 19-25. PMID 22901983 DOI: 10.1016/J.Eururo.2012.08.002 |
0.301 |
|
| 2013 |
Bouchard F, Rimac G, Blouin A, Lefebvre V, Têtu B, Hovington H, Lemay C, Fradet V, Lacombe L, Fradet Y, Dujardin T, Tiguert R, Pouliot F. 2199 GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2108 |
0.325 |
|
| 2013 |
Blouin A, Rimac G, Bouchard F, Lemay C, Fradet V, Caron A, Fradet Y, Lacombe L, Dujardin T, Tigert R, Beauregard J, Pouliot F. 241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1621 |
0.44 |
|
| 2012 |
Trudel D, Labbé DP, Bairati I, Fradet V, Bazinet L, Têtu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecologic Oncology. 126: 491-8. PMID 22564714 DOI: 10.1016/J.Ygyno.2012.04.048 |
0.342 |
|
| 2012 |
Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. European Urology. 62: 88-96. PMID 22209174 DOI: 10.1016/J.Eururo.2011.12.021 |
0.502 |
|
| 2012 |
Otzetov A, Fradet V, Levesque J, Bergeron A, Lacombe L, Dujardin T, Tiguert R, Fradet Y. S84 URANARY PCA3 AND CANCER PROGRESSION UNDER ACTIVE SURVILLANCE OF PROSTATE CANCER European Urology Supplements. 11: 154. DOI: 10.1016/S1569-9056(13)60277-8 |
0.478 |
|
| 2011 |
Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. The Journal of Urology. 186: 2228-32. PMID 22014796 DOI: 10.1016/j.juro.2011.07.119 |
0.417 |
|
| 2011 |
Mauermann J, Pouliot F, Fradet V. Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers. World Review of Nutrition and Dietetics. 102: 156-71. PMID 21865830 DOI: 10.1159/000327805 |
0.464 |
|
| 2011 |
Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E. SRD5A polymorphisms and biochemical failure after radical prostatectomy. European Urology. 60: 1226-34. PMID 21715084 DOI: 10.1016/J.Eururo.2011.06.020 |
0.322 |
|
| 2011 |
Fradet V, Lévesque J, Bergeron A, Lacombe L, Dujardin T, Tiguert R, Fradet Y. UP-02.184 Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer Urology. 78: S324. DOI: 10.1016/S1569-9056(13)60277-8 |
0.565 |
|
| 2011 |
Fradet V, Neveu B, Moreel X, Bergeron A, Larue H, Fradet Y. UP-02.084 Active Inflammatory State and Reactivity of Normal Prostate Epithelium and Aggressive Prostate Cancer Urology. 78: S288-S289. DOI: 10.1016/J.Urology.2011.07.902 |
0.549 |
|
| 2011 |
Fradet V, Lodde M, Mauermann J, Caron A, Lacombe L, Dujardin T, Fradet Y. POD-07.07 Long-Term Cancer Outcomes After Radical Prostatectomy and Selective Salvage Radiotherapy in 1670 Pt2-3N0M0 Patients by Margins Status: Quantification of Overtreatment with Adjuvant Radiotherapy for all Positive Margins Urology. 78: S25. DOI: 10.1016/J.Urology.2011.07.457 |
0.373 |
|
| 2011 |
Fradet V, Neveu B, Morel X, Julien P, Bergeron A, Larue H, Fradet Y. UP-02.229 Anti-Inflammatory Effects of Fish Oil (Omega-3 Fatty Acids) on Normal Human Prostate Epithelium Urology. 78: S340-S341. DOI: 10.1016/J.Urology.2011.07.1047 |
0.378 |
|
| 2010 |
Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 256: 176-83. PMID 20505068 DOI: 10.1148/Radiol.10091147 |
0.322 |
|
| 2010 |
Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2499-504. PMID 20406931 DOI: 10.1200/JCO.2009.26.9597 |
0.346 |
|
| 2009 |
Reese AC, Fradet V, Witte JS. Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. Journal of Nutrigenetics and Nutrigenomics. 2: 149-58. PMID 19776642 DOI: 10.1159/000235565 |
0.42 |
|
| 2009 |
Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2559-66. PMID 19318492 DOI: 10.1158/1078-0432.Ccr-08-2503 |
0.367 |
|
| 2009 |
Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. The Journal of Urology. 181: 1628-33; discussion . PMID 19233388 DOI: 10.1016/j.juro.2008.11.107 |
0.439 |
|
| 2009 |
Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. THE RELATIONSHIP BETWEEN LOCAL UROLOGIST DENSITY AND PROSTATE, BLADDER, AND KIDNEY CANCER MORTALITY Journal of Urology. 181: 163-163. DOI: 10.1016/S0022-5347(09)60468-7 |
0.501 |
|
| 2009 |
Conti S, Dall'Era M, Fradet V, Cowan JE, Simko J, Carroll PR. PATHOLOGIC OUTCOMES IN MEN MEETING CRITERIA FOR ACTIVE SURVEILLANCE OF PROSTATE CANCER Journal of Urology. 181: 60-60. DOI: 10.1016/S0022-5347(09)60179-8 |
0.542 |
|
| 2009 |
Karl A, Rittler P, Buchner A, Fradet V, Walther S, Stief CG. RISK OF MALNUTRITION IN UROLOGICAL PATIENTS Journal of Urology. 181: 8-8. DOI: 10.1016/S0022-5347(09)60033-1 |
0.307 |
|
| 2008 |
Fradet V, Sheehy O, Saad F, LeLorier J. Statins and superficial bladder cancer evolution after diagnosis: A population-based study Journal of Clinical Oncology. 26: 22047-22047. DOI: 10.1200/Jco.2008.26.15_Suppl.22047 |
0.408 |
|
| 2008 |
Fradet V, Paciorek A, Knight SJ, Carroll PR, Chan JM. INTAKE OF A HEALTHY DIET PATTERN AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH PROSTATE CANCER Journal of Urology. 179: 608-609. DOI: 10.1016/S0022-5347(08)61782-6 |
0.466 |
|
| 2008 |
Fradet V, Cheng I, Casey G, Witte JS. DIETARY LONG-CHAIN OMEGA-3 FATTY ACIDS, COX2 GENE POLYMORPHISM, AND AGGRESSIVE PROSTATE CANCER Journal of Urology. 179: 149-149. DOI: 10.1016/S0022-5347(08)60427-9 |
0.478 |
|
| 2006 |
Chun K, Briganti A, Steuber T, Walz J, Lebeau T, Fradet V, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz P. THE 2002 AJCC PATHOLOGICAL T2 SUBSTAGES CONFER NO PROGNOSTIC INFORMATION ON THE RATE OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS WITH PATHOLOGICALLY ORGAN CONFINED DISEASE AT RADICAL PROSTATECTOMY European Urology Supplements. 5: 279. DOI: 10.1016/S1569-9056(06)61029-4 |
0.495 |
|
| 2005 |
Fradet V, McCormack M, Perrotte P, Karakiewicz P, Saad F. An epidural abscess following transrectal ultrasound-guided biopsies of the prostate. The Canadian Journal of Urology. 12: 2899-900. PMID 16401377 |
0.393 |
|
| 2004 |
Fradet V, Lessard L, Mes-Masson A, Begin LR, Perrotte P, Karakiewicz PI, Saad F. 1093: NFKB Expression Predicts Biochemical Recurrence in Patients with Positive Margin Prostate Cancer Journal of Urology. 171: 288-288. DOI: 10.1016/S0022-5347(18)38330-7 |
0.547 |
|
| Show low-probability matches. |